|
|
||||||||
Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, California 90502
Ikegami, Machiko, Celso M. Rebello, and Alan H. Jobe.
Surfactant inhibition by plasma: gestational age and surfactant treatment effects in preterm lambs. J. Appl.
Physiol. 81(6): 2517-2522, 1996.
The preterm
infant with respiratory distress syndrome has edematous lungs and small
amounts of surfactant that do not function normally. We reported that
surfactant recovered from preterm lambs after surfactant treatment can
have decreased sensitivity to inhibition of surface tension by plasma.
We asked whether this augmented resistance to inhibition was dependent
on lung development (gestational age) by testing sensitivity to plasma
inhibition of 1) endogenous surfactant from preterm lambs and 2)
surfactant from preterm lambs after treatment with an organic
solvent-extracted natural sheep surfactant. Surfactant recovered after
surfactant treatment of 121- or 128-days-gestation lambs had the same
sensitivity to plasma inhibition as did the surfactant used to treat
the lambs. Surfactant recovered from 134-days-gestation lambs had
decreased sensitivity to inhibition. Lung maturation is a variable
influencing surfactant inhibition by plasma.
respiratory distress syndrome; surface tension; phosphatidylcholine; lung development; Wilhelmy balance
SURFACTANT METABOLISM AND FUNCTION in the alveoli are
linked by interrelated pathways that involve changes in the structural forms, surfactant protein content, and biophysical properties of the
alveolar surfactant (2, 30). This metabolism-function relationship is
disrupted during lung injuries characterized by alveolar edema and
inflammation (9, 21) and with preterm delivery and ventilation of the
immature lung (20). The abnormalities that have been characterized in
the preterm lung include decreased pool sizes of surfactant lipids
(19), decreased amounts of the surfactant-specific proteins (26, 28,
30), increased minimum surface tensions (1), sequestration of
surfactant within clots or hyaline membranes (7), and inhibition of
surfactant function by soluble proteins in pulmonary edema fluid (12,
13).
Different surfactants also will have different characteristics. For
example, relative to surfactant from the adult lung, surfactant from
the preterm lung has a decreased density and an increased rate of
conversion from surface-active to -inactive forms that correlated with
a decreased surfactant protein-A (SP-A) content relative to
phospholipids (28). Lipid-only surfactants are extremely sensitive to
inhibition of surfactant function by soluble proteins, and the
surfactant proteins SP-A, SP-B, and SP-C seem to act cooperatively to
preserve the biophysical properties of surfactant (8, 10). The addition
of SP-A to a surfactant that contains SP-B and SP-C can improve the
function of the surfactant when administered with plasma to preterm
rabbits (31). We recently reported (29) that surfactant recovered from
lambs that received prenatal corticosteroid had improved function
relative to surfactant from lambs not treated prenatally with
corticosteroids. This result suggested that the maturational state of
the lung might be a variable that would influence the sensitivity of
surfactant to inactivation by plasma. Therefore, we hypothesized that
lung maturation would influence the sensitivity of the endogenous
surfactant pool to surfactant inhibition by plasma. We also have
reported that surfactants used to treat the preterm lung (24) and the
lungs of adult rabbits injured with
N-nitroso-N-methylurethane
have improved resistance to inactivation by plasma after recovery from
the lungs (27). We also hypothesized that the ability of the preterm
lung to confer resistance to plasma inhibition to a surfactant used for
treatment will depend on the maturational state of the lung.
Surfactant used for treatment. An
organic solvent extract of sheep surfactant was used as the surfactant
for those lambs treated with surfactant because it is similar to the
natural-source surfactants used clinically (18). Sheep surfactant was
isolated from alveolar lavage of adult sheep lungs by a three-step
centrifugation procedure that includes a 0.8 M sucrose density gradient
(13). The surfactant was mixed with chloroform-methanol (2:1) and mixed
well with a magnetic stirrer. The solution was filtered through
Whattman no. 1 filter paper to remove precipitated proteins. The
residual surfactant lipids and proteins were extracted two more times
with chloroform-methanol-saline (2:1:1). The extraction procedure
removes SP-A but not SP-B or SP-C. The lipid extract of sheep
surfactant was dried on a round bottom flask and suspended by using
glass beads in 0.9% NaCl at a concentration of 25 mg/ml. This
surfactant is highly surface active and effective for the treatment of
surfactant deficiency in the preterm lambs (15).
Preterm lambs used for surfactant
recovery. These experiments involve the use of
surfactant from preterm lambs at different gestational ages for two
protocols: the recovery of endogenous surfactant and the recovery of
surfactant after surfactant treatment. For the studies using endogenous
surfactant, preterm lambs were delivered at 128 days gestation
(n = 9) and 134 days gestation (n = 5) and ventilated for 1 h to
allow for secretion of the endogenous surfactant (17). We did not
ventilate these premature lambs for longer periods to avoid death and
severe lung injury (13). Surfactant was pooled from several
128-days-gestation lambs to yield sufficient material for testing.
Lambs more immature than 128 days gestation were not used for studies
of endogenous surfactant because the pool size of surfactant is too
small (28). For studies of surfactant recovered after surfactant
treatment, lambs were delivered at 121 days gestation
(n = 4), 128 days gestation
(n = 4), and 134 days gestation
(n = 4); treated with surfactant; and
ventilated for 3 h to permit the treatment surfactant to function within the alveolar environment (15).
Preterm lambs were delivered by cesarean section as previously
described (15). Briefly, each pregnant ewe was sedated (1 g im
ketamine) and given spinal-epidural anesthesia (10 ml 2% lidocaine-0.5% marcaine solution, 1:1, vol/vol). The anterior neck of
the ewe was anesthetized (2% sq lidocaine), and an endotracheal tube
was tied into the trachea followed by ventilation with a 10 ml/kg tidal
volume by using a Harvard large-animal volume ventilator. The fetal
head was exposed through midline abdominal and uterine incisions, and
the fetus was anesthetized (10 mg/kg im ketamine and 0.1 mg/kg im
acepromazine). The anterior fetal neck was anesthetized (2% sq
lidocaine), and an endotracheal tube was tied into the trachea. Fetal lung fluid that could be easily aspirated by
syringe was withdrawn, and the trachea tube was clamped. The umbilical cord was cut, and each lamb was weighed. The lambs to be treated with
surfactant received 100 mg/kg of the lipid extract of sheep surfactant
before the initiation of ventilation (15). The lambs were ventilated by
using time-cycled, pressure-limited ventilators (Sechrist Industries,
Anaheim, CA) with initial settings as follows: inspired
O2 fraction
(FIO2), 1.0; peak
inspiratory pressure (PIP), 35 cmH2O; positive end-expiratory
pressure (PEEP), 3 cmH2O; inspiratory time, 0.7 s; breathing rate, 40 breaths/min; and flow, 10 l/min. PIP was subsequently adjusted for each animal in an attempt to
achieve arterial PCO2 values of ~45
Torr, as assessed by frequent blood gas measurements. An
attempt also was made to regulate PIP by adjusting tidal volumes to
7-10 ml/kg, as measured with a pneumotachometer (15). PIP values
>35 cmH2O for the lambs treated
with surfactant and 40 cmH2O for
the lambs not treated with surfactant were not used to avoid
pneumothorax. FIO2 was
adjusted for the surfactant-treated lambs to keep arterial
PO2 between 100 and 200 Torr.
FIO2 was kept at 1.0 for the
lambs not treated with surfactant. The other ventilator settings were
not changed.
A 5-Fr catheter was advanced into the aorta via an umbilical artery,
and frequent blood samples were obtained for blood gas analysis. A
constant infusion of 5% dextrose (4 ml · kg Alveolar lavage and surfactant
isolation. At the end of the period of ventilation, the
lambs were deeply anesthetized (50 mg/kg iv pentobarbital sodium) and
exsanguinated. The lungs were removed from the thorax and filled by
gravity with 0.9% NaCl at 4°C until fully distended. The alveolar
lavage was recovered by using a syringe for premature lamb lung (20).
The procedure was repeated five times, and the recovered alveolar
lavages were pooled. The ewes that provided the lambs were ventilated
for 1 h, killed with an overdose of pentobarbital sodium, and the lungs were removed from the chest. An alveolar wash was recovered, and surfactant was isolated from alveolar lavages by centrifugation (28).
After an initial centrifugation at 140 g for 10 min, the supernatant was
centrifuged at 40,000 g for 15 min.
The pellet containing large-aggregate surfactant was resuspended in
saline and centrifuged at 40,000 g for
15 min over 0.8 M sucrose. The interface was aspirated, diluted with
saline, and centrifuged at 40,000 g
for 15 min. The surfactant pellet then was resuspended in a small
amount of saline for subsequent analysis.
Sensitivity of surfactant to plasma
inhibition. Minimum surface tensions were measured by
using a Wilhelmy balance with a platinum dipping plate after the fourth
cycle from a maximum area of 64 cm2 to a minimum area of 12.8 cm2 at a temperature of 37°C
(13). Area change was 3 min/cycle. Each surfactant was diluted in 35 ml
saline to a final concentration of 0.05 mg lipid/ml. Plasma was then
added and mixed with a glass rod by hand to achieve final
concentrations of 0.4, 0.6, and 0.8 mg/ml protein, and surface tension
measurements were repeated (6, 23). Surface area-surface tension loops
were overlapping by the third or fourth cycle. Surface tension values
at the fourth cycle are reported in
RESULTS (27).
Material and analytical techniques.
Lipids were extracted from surfactant samples with chloroform-methanol
(2:1, vol/vol). After the aliquots of lipid extracts were dried, total
lipids were determined by weight with a Cahn Electrobalance
(Cahn-Ventron, Cerritos, CA). Saturated phosphatidylcholine
(PCsat) was isolated from lipid
extracts by neutral alumina column chromatography after exposure to
osmium tetroxide and quantified by phosphorus assay (3, 22). Monomer
standard bovine serum albumin (Miles Laboratories, Elkhart, IN) was
iodinated with chloramine T (20). After dialysis, over 97% of the
radiolabel was protein bound, as indicated by trichloroacetic acid
precipitation. SP-A was measured by radioimmunoassay (14).
Data analysis. All values are
expressed as means ± SE. Differences between groups were tested by
analysis of variance followed by the Student-Newman-Keuls
multiple-comparison procedure.
Plasma inhibition of surfactant.
Because the composition of plasma from preterm and adult sheep will
have different compositions, we initially asked whether the source of
the plasma would be a variable for these experiments. Surfactant
recovered from lambs at 121, 128, and 134 days gestation that had been
treated with surfactant was mixed with plasma from the lambs at the
same gestation and compared with plasma from the ewes (Fig.
1). Inhibition of minimum surface tension
by plasma from the ewes or the preterm lambs was similar for surfactant
at each gestation. Therefore, aliquots of plasma from one adult sheep
were frozen and used as the plasma source for all subsequent
measurements.
Endogenous surfactant. The
128-days-gestation lambs were in severe respiratory failure with an
average arterial PCO2 of 87 Torr at 1 h of age, despite the use of 31 ± 2 cmH2O ventilatory pressure
(PIP Table 1.
Animals used to recover endogenous surfactant
1 · h
1)
was given, and blood pressure was recorded continuously. Rectal temperature was maintained at the normal body temperature for lambs of
38-39°C by using radiant heat and heating pads. The animals treated with surfactant received 10 µCi of
125I-albumin at 2 h of age via the
arterial catheter, and 1 h later a final blood sample was obtained for
measurements of radiolabeled albumin and hemoglobin. Intravascular
albumin was used as an indicator of transvascular pulmonary edema (20).
Fig. 1.
Evaluation of source of plasma on inhibition of surface tension.
Large-aggregate surfactant recovered from surfactant-treated lambs
after delivery at 121, 128, and 134 days gestation was mixed with
increasing amounts of plasma from same gestation lambs or with plasma
from adult ewes (n = 4 for each
group). Plasma from preterm lambs and ewes inhibited minimum surface
tensions similarly at each gestational age. d, Day.
[View Larger Version of this Image (14K GIF file)]
PEEP) (Table 1). The
134-days-gestation lambs were successfully ventilated on lower
pressures. The amount of PCsat and
SP-A recovered in the large-aggregate surfactant was very low for the
128-days-gestation lambs. Both
PCsat and SP-A were increased at
134 days gestation. The pool sizes for these surfactant components
increased further for surfactant from the ewes.
Age
n
Body Wt, kg
Values at 1 h
In Alveolar Lavage
pH
PaCO2, Torr
PaO2/FIO2
, Torr
PIP
PEEP, cmH2O PCsat,
µmol/kg
SP-A, mg/kg
128 Days gestation
9
2.7 ± 0.3
7.13 ± 0.06
87 ± 13
66 ± 12
31 ± 2
1.0 ± 0.2
0.08 ± 0.02
134 Days gestation
5
3.2 ± 0.1*
7.33 ± 0.01*
44 ± 1*
182 ± 42*
23 ± 1*
3.0 ± 0.7*
0.14 ± 0.01*
Adult sheep
4
61.2 ± 2.4
11.3 ± 2.4
1.04 ± 0.07

Values are means ± SE; n = no. of lambs.
PaCO2, arterial
PCO2; PaO2, arterial
PO2;
FIO2, inspiratory O2
fraction; PIP, peak inspiratory pressure; PEEP, positive
end-expiratory pressure; PCsat, saturated
phosphatidylcholine; SP-A, surfactant protein-A.
*
P < 0.05 vs. 128-days-gestation lambs;
P < 0.05 vs. 128- and 134-days gestation lambs.
The minimum surface tensions achieved on surface area compression for
the endogenous surfactants from 128-days-gestation, 134-days-gestation,
and adult sheep were similar and were <5 dyn/cm (Fig.
2). The addition of 0.4 mg plasma
protein/ml had little effect on the minimum surface tension
measurements. However, the surfactant from the 128-days-gestation lambs
was the most sensitive to inhibition at higher plasma protein
concentrations. The surfactant from the 134-days-gestation lambs was
intermediate in sensitivity between the surfactant from the more
immature lambs and the surfactant from adult sheep. Surfactant from
adult sheep had a minimal surface tension <10 dyn/cm at a plasma
concentration of 0.8 mg/ml.
Surfactant recovered after surfactant treatment. After 3-h ventilation, the lambs treated with surfactant had similar blood gas values and ventilatory requirements (Table 2). This result demonstrates the efficacy of surfactant even for very preterm lambs. There also was no difference in the amount of intravascular albumin that was recovered by alveolar lavage. Therefore, the amount of protein available to interfere with surfactant function was similar at the three gestational ages.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The organic solvent extract surfactant used to treat the preterm lambs
had a low minimum surface tension in the absence of plasma (Fig.
3A).
However, this surfactant was much more sensitive to inhibition by
plasma than was the natural surfactant from adult sheep. The
surfactants recovered from the preterm lambs at 121 or 128 days
gestation, treated with surfactant, and ventilated for 3 h were similar
in sensitivity to inhibition by plasma and not different from the lipid
extract surfactant used to treat the lambs (Fig.
3B). However, surfactant from the
134-days-gestation lambs was more resistant to inhibition by plasma.
This study demonstrates that the endogenous surfactant recovered from the preterm lung is more sensitive to inhibition by plasma proteins than is surfactant from the adult. This sensitivity increases as gestation decreases. Similarly, surfactant used for treatment can become less sensitive to inhibition by plasma after exposure to the moderately preterm lung, an effect that is lost in the more preterm lung. These results add to the accumulating information indicating that surfactant deficiency of the preterm lambs with respiratory distress syndrome results from a number of factors. The surfactant pool size is low (19), and surfactant from preterm lambs is less effective as a treatment surfactant for surfactant deficiency (28). Several factors contribute to the abnormalities of surfactant from the preterm animals. SP-A content is decreased, and the rate of form conversion from large-aggregate active surfactant to small-aggregate inactive surfactant is increased (28). We now show increased sensitivity to inhibition by plasma proteins. Inhibition of surfactant in infants with respiratory distress syndrome is thought to contribute to deterioration in lung function and the need for subsequent doses of surfactant (11, 25). Airway samples from infants with respiratory distress syndrome have high minimum surface tensions, but the surfactant, when separated from soluble proteins, has good biophysical properties when tested in vitro (12). The infant with respiratory distress syndrome often has severe pulmonary edema as a component of the disease process (16, 20). An increased sensitivity of the surfactant of the preterm animal to plasma inhibition will compound the problem of surfactant inactivation. We did not find that plasma from preterm lambs or adult sheep had different abilities to inactivate surfactant.
Surfactants for clinical use from animal lung sources contain no SP-A, have different lipid compositions, and contain different amounts of SP-B and SP-C (8, 23). These surfactants were shown previously to be relatively sensitive to inhibition by plasma or plasma components (4, 6, 8). Animal-source surfactants with variable SP-B or SP-B and SP-C contents have different resistances to inactivation by proteins (8). We used an SP-A-deficient surfactant for these experiments to mimic the clinical situation. The preterm lambs treated with surfactant for these protocols did not have much pulmonary edema. The amount of labeled albumin given by intravascular injection that was recovered in the alveolar washes was low and comparable to measurements in term newborn lambs (20). We previously reported much higher recoveries of radiolabeled albumin in 121- and 128-days-gestation lambs (20). For present protocols, we kept tidal volumes at <10 ml/kg in an attempt to avoid volutrauma (5). We tried to avoid injury to the lungs to permit the comparison of surfactants recovered from lungs that had not been exposed to large amounts of protein-rich edema. We found that the more mature lung altered the surfactant used for treatment to make it more similar to the natural sheep surfactant. A likely explanation for this effect is the contribution of components from the preterm lung to the exogenously administered surfactant. We previously found SP-A in surfactant that did not initially contain SP-A after treatment of preterm lambs (15). Also, when 5% natural sheep surfactant is simply mixed with a bovine lung-derived surfactant that does not contain SP-A (Survanta, Ross Products, Columbus, OH), it makes that surfactant as resistant to inhibition by plasma as natural sheep surfactant (6). This effect of improved resistance to inhibition by plasma proteins was also found after surfactant treatment of rabbits with lungs injured with N-nitroso-N-methylurethane and after corticosteroid treatment of the fetal sheep (24, 27). Therefore, a general characteristic of the more mature lung is the ability to increase the resistance to plasma inhibition of surfactants used for treatment. This effect does not occur in the very preterm lung.
Another interaction of surfactant used for treatment with the preterm lung also was characterized by evaluating surfactant treatment responses of surfactant recovered from premature lamb lungs. Surfactants recovered after treatment of preterm lambs were more effective at improving compliances and lung volumes of surfactant-deficient preterm rabbits than were the surfactants used to treat the lambs (15). This phenomenon of surfactant "activation" was thought to occur by the association of endogenous surfactant components with the surfactant used for treatment. Therefore, the improved surfactant treatment responses and the enhanced resistance to inhibition by plasma may occur by similar mechanisms. Neither effect occurs in the very preterm lung (6).
This study describes two new mechanisms by which the very preterm infant have compromised surfactant function. The endogenous alveolar surfactant pool may have increased sensitivity to inhibition by plasma. Many plasma components as well as lipids, other proteins such as hemoglobin, and bilirubin also can inhibit surfactant function (10, 11). Sensitivity of surfactant from the preterm lambs to other inhibitors has not been evaluated, but it is also likely to be increased because the surfactant proteins also tend to protect from inactivation by other substances (10). Surfactants used for treatment of respiratory distress syndrome are relatively sensitive to inhibition by plasma, and the very preterm lung cannot augment resistance to inhibition. This result is consistent with the less consistent response to surfactant treatment and the need for repeated doses of surfactant for very preterm infants.
This research was supported by an National Institute of Child Health and Human Development Grant HD-12714 and by the Conselho Nacional de Desenvolvimento Cientifico Tecnologico Brazil Scholarship to Celso M. Rebello.
Address for reprint requests: M. Ikegami, Dept. of Pediatrics, Harbor-UCLA Medical Center, 1124 W. Carson St., RB-1, Torrance, CA 90502.
Received 22 April 1996; accepted in final form 30 July 1996.
| 1. | Avery, M. E., and J. Mead. Surface properties in relation to atelectasis and hyaline membrane disease. Am. J. Dis. Child. 97: 517-523, 1959. |
| 2. | Baritussio, A., A. Alberti, D. Quaglino, A. Pettenazzo, D. Dalzoppo, L. Sartori, and I. Pasquali-Ronchetti. SP-A, SP-B, and SP-C in surfactant subtypes around birth: reexamination of alveolar life cycle of surfactant. Am. J. Physiol. 266 (Lung Cell. Mol. Physiol. 10): L436-L447, 1994. |
| 3. | Bartlett, G. R. Phosphorus assay in column chromatography. J. Biol. Chem. 234: 466-468, 1959. |
| 4. | Bruni, R., B. R. Fan, R. David-Chu, H. W. Taeusch, and F. J. Walther. Inactivation of surfactant in rat lungs. Pediatr. Res. 39: 236-240, 1996. |
| 5. | Carlton, D. P., J. J. Cummings, R. G. Scheerer, F. R. Poulain, and R. D. Bland. Lung overexpansion increases pulmonary microvascular protein permeability in young lambs. J. Appl. Physiol. 69: 577-583, 1990. |
| 6. | Chen, C. M., M. Ikegami, T. Ueda, D. H. Polk, and A. H. Jobe. Exogenous surfactant function in very preterm lambs with and without fetal corticosteroid treatment. J. Appl. Physiol. 78: 955-960, 1995. |
| 7. | Gunther, A., M. Kalinowski, S. Rosseau, and W. Seeger. Surfactant incorporation markedly alters mechanical properties of a fibrin clot. Am. J. Respir. Cell Mol. Biol. 13: 712-718, 1995. |
| 8. | Gunther, A., and W. Seeger. Resistance to surfactant inactivation. In: Surfactant Therapy for Lung Disease, edited by B. Robertson, and H. W. Taeusch. New York: Dekker, 1995, p. 269-292. |
| 9. | Gunther, A., C. Siebert, R. Schmidt, S. Ziegler, F. Grimminger, M. Yabut, B. Temmesfeld, D. Walmrath, H. Morr, and W. Seeger. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am. J. Respir. Crit. Care Med. 153: 176-184, 1996. |
| 10. | Holm, B. A. Surfactant inactivation in the adult respiratory distress syndrome. In: Pulmonary Surfactant: From Molecular Biology to Clinical Practice, edited by B. Robertson, L. M. G. van Golde, and J. J. Batenburg. Amsterdam: Elsevier, 1993, p. 665-684. |
| 11. | Ikegami, M. Surfactant inactivation. In: New Therapies for Neonatal Respiratory Failure, edited by B. R. Boyton, W. A. Carlo, and A. H. Jobe. New York: Cambridge Univ. Press, 1994, p. 36-48. |
| 12. | Ikegami, M., H. Jacobs, and A. H. Jobe. Surfactant function in the respiratory distress syndrome. J. Pediatr. 102: 443-447, 1993. |
| 13. | Ikegami, M., A. H. Jobe, and T. Glatz. Surface activity following natural surfactant treatment in preterm lambs. J. Appl. Physiol. 51: 306-312, 1981. |
| 14. | Ikegami, M., D. Polk, B. Tabor, J. Lewis, T. Yamada, and A. H. Jobe. Corticosteroid and thyrotropin-releasing hormone effects on preterm sheep lung function. J. Appl. Physiol. 70: 2268-2278, 1991. |
| 15. | Ikegami, M., T. Ueda, D. Absolom, C. Baxter, E. Rider, and A. H. Jobe. Changes in exogenous surfactant in ventilated preterm lambs lungs. Am. Rev. Respir. Dis. 148: 837-844, 1993. |
| 16. | Jackson, J. C., A. P. MacKenzie, E. Y. Chi, T. A. Standaert, W. E. Truog, and W. A. Hodson. Mechanisms for reduced total lung capacity at birth and during hyaline membrane disease in premature newborn monkeys. Am. Rev. Respir. Dis. 142: 413-419, 1990. |
| 17. | Jacobs, H., A. Jobe, M. Ikegami, and S. Jones. Accumulation of alveolar surfactant following delivery and ventilation of premature lambs. Exp. Lung Res. 8: 125-140, 1985. |
| 18. | Jobe, A. H. Pulmonary surfactant therapy. New Engl. J. Med. 328: 861-868, 1993. |
| 19. | Jobe, A., and M. Ikegami. Surfactant for the treatment of respiratory distress syndrome. Am. Rev. Respir. Dis. 136: 1256-1275, 1987. |
| 20. | Jobe, A. H., J. Jacobs, M. Ikegami, and D. Berry. Lung protein leaks in ventilated lambs: effect of gestational age. J. Appl. Physiol. 58: 1246-1251, 1985. |
| 21. | Lewis, J. F., M. Ikegami, and A. H. Jobe. Altered surfactant function and metabolism in rabbits with acute lung injury. J. Appl. Physiol. 69: 2303-2310, 1990. |
| 22. | Mason, R. J., J. Nellenbogen, and J. A. Clements. Isolation of saturated phosphatidylcholine with osmium tetroxide. J. Lipid Res. 17: 281-284, 1976. |
| 23. | Mizuno, K., M. Ikegami, C.-M. Chen, T. Ueda, and A. H. Jobe. Surfactant protein-B supplementation improves in vivo function of a modified natural surfactant. Pediatr. Res. 37: 271-276, 1995. |
| 24. | Rebello, C. M., M. Ikegami, D. H. Polk, and A. H. Jobe. Postnatal lung responses and surfactant function after fetal or maternal corticosteroid treatment of preterm lambs. J. Appl. Physiol. 80: 1674-1680, 1996. |
| 25. | Segerer, H., P. Stevens, B. Schadow, R. Maier, E. Kattner, H. Schwarz, T. Curstedt, B. Robertson, and M. Obladen. Surfactant substitution in ventilated very low birth weight infants: factors related to response types. Pediatr. Res. 30: 591-596, 1991. |
| 26. | Snyder, J. M., and C. R. Mendelson. Induction and characterization of the major surfactant apoprotein during rabbit fetal development. Biochim. Biophys. Acta 920: 226-236, 1987. |
| 27. | Ueda, T., and M. Ikegami. Change in properties of exogenous surfactant in injured rabbit lung. Am. J. Respir. Crit. Care Med. 153: 1844-1849, 1996. |
| 28. | Ueda, T., M. Ikegami, and A. H. Jobe. Developmental changes of sheep surfactant: in vivo function and in vitro subtype conversion. J. Appl. Physiol. 76: 2701-2706, 1994. |
| 29. | Ueda, T., M. Ikegami, D. Polk, K. Mizuno, and A. Jobe. Effects of fetal corticosteroid treatments on postnatal surfactant function in preterm lambs. J. Appl. Physiol. 79: 846-851, 1995. |
| 30. | Weaver, T. E., and J. A. Whitsett. Function and regulation of expression of pulmonary surfactant-associated proteins. Biochem. J. 273: 249-264, 1991. |
| 31. | Yukitake, K., C. L. Brown, M. A. Schlueter, J. A. Clements, and S. Hawgood. Surfactant apoprotein A modifies the inhibitory effect of plasma proteins on surfactant activity in vivo. Pediatr. Res. 37: 21-25, 1995. |
This article has been cited by other articles:
![]() |
D. McCurnin, S. Seidner, L.-Y. Chang, N. Waleh, M. Ikegami, J. Petershack, B. Yoder, L. Giavedoni, K. H. Albertine, M. J. Dahl, et al. Ibuprofen-Induced Patent Ductus Arteriosus Closure: Physiologic, Histologic, and Biochemical Effects on the Premature Lung Pediatrics, May 1, 2008; 121(5): 945 - 956. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. te Pas and F. J. Walther A Randomized, Controlled Trial of Delivery-Room Respiratory Management in Very Preterm Infants Pediatrics, August 1, 2007; 120(2): 322 - 329. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. SEIDNER, A. H. JOBE, J. J. COALSON, and M. IKEGAMI Abnormal Surfactant Metabolism and Function in Preterm Ventilated Baboons Am. J. Respir. Crit. Care Med., December 1, 1998; 158(6): 1982 - 1989. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ikegami, T. R. Korfhagen, J. A. Whitsett, M. D. Bruno, S. E. Wert, K. Wada, and A. H. Jobe Characteristics of surfactant from SP-A-deficient mice Am J Physiol Lung Cell Mol Physiol, August 1, 1998; 275(2): L247 - L254. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Wada, A. H. Jobe, and M. Ikegami Tidal volume effects on surfactant treatment responses with the initiation of ventilation in preterm lambs J Appl Physiol, October 1, 1997; 83(4): 1054 - 1061. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. DAVIS, A. H. JOBE, D. HÄFNER, and M. IKEGAMI Lung Function in Premature Lambs and Rabbits Treated with a Recombinant SP-C Surfactant Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 553 - 559. [Abstract] [Full Text] |
||||
![]() |
M. IKEGAMI, K. WADA, G. A. EMERSON, C. M. REBELLO, R. E. HERNANDEZ, and A. H. JOBE Effects of Ventilation Style on Surfactant Metabolism and Treatment Response in Preterm Lambs Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 638 - 644. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |